Recruiting soon

Durvalumab with EP and Chemoradiotherapy in Limited-stage Small-cell Lung Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study is treating limited-stage small-cell lung cancer patients with durvalumab, etoposide, and chemoradiotherapy. It aims to assess how this treatment affects progression-free survival.

What is being tested

Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance

Drug
Who is being recruted

Bronchial Neoplasms+7

+ Carcinoma, Bronchogenic

+ Lung Diseases

Over 18 Years
+23 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: July 2025
See protocol details

Summary

Principal SponsorQian Chu
Study ContactQian Chu, Head of the Thoracic Cancer De
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 31, 2025

Actual date on which the first participant was enrolled.

This clinical trial focuses on improving treatment for people with limited-stage small-cell lung cancer (LS-SCLC), a fast-growing type of lung cancer. About a third of individuals are diagnosed with LS-SCLC, which is traditionally treated with a combination of chemotherapy and radiotherapy. However, most patients still experience relapse, and only a small percentage achieve a cure. This study seeks to explore the potential of adding an immune therapy called durvalumab, both before and after the standard chemotherapy and radiotherapy, to enhance the effectiveness of existing treatments and potentially improve the chances of long-term survival. Participants in this study receive durvalumab alongside the usual chemotherapy drugs, etoposide and a platinum compound, before they undergo the standard chemoradiotherapy. After completing this combined treatment, durvalumab is given again as a follow-up therapy to see if it can help prevent the cancer from returning. The study evaluates how well this approach works and monitors the safety and potential side effects of using durvalumab in this way. The goal is to find out if this combined treatment can offer better outcomes for patients with limited-stage small-cell lung cancer.

Official TitleA Phase II Study of Durvalumab Combined With EP Prior to Chemoradiotherapy and Followed by Durvalumab as Consolidation for Patients With Limited-stage Small-cell Lung Cancer (CONCUR Study)
NCT07055581
Principal SponsorQian Chu
Study ContactQian Chu, Head of the Thoracic Cancer De
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bronchial NeoplasmsCarcinoma, BronchogenicLung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsSmall Cell Lung Carcinoma

Criteria

8 inclusion criteria required to participate
1.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
2.Histologically or cytologically confirmed small cell lung cancer
3.Limited-stage, defined as stage I-III SCLC (T any, N any, M0). Patients who are Stage I or II must be medically inoperable as determined by investigator.
4.Age > 18 years.
Show More Criteria
15 exclusion criteria prevent from participating
1.Patients with extensive disease small-cell lung cancer.
2.Patients who previously received radiotherapy to the thorax or chemotherapy for small cell lung cancer.
3.Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology. Patients with mixed histology tumors with predominant SCLC histology are allowed.
4.Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers